IVF HARTMANN Holding AG
VBSN
ISIN CH0187624256 / Valor 18762425
IVF HARTMANN Holding AG
UMushroom community rating:
About company
IVF HARTMANN Holding AG, headquartered in Neuhausen am Rheinfall, Switzerland, is a subsidiary of the HARTMANN GROUP based in Heidenheim, Germany, and has been a prominent player in the Swiss medical consumables sector for over 150 years. With approximately 330 employees in Switzerland, the company focuses on developing and providing innovative medical products and services across various segments, including incontinence care, wound treatment, risk prevention in hospitals (notably in operating rooms), and first aid. These core areas are complemented by additional product segments such as cotton and therapeutic plasters, enhancing the company's medical expertise. IVF HARTMANN combines its products with customized services to meet the evolving needs of its clients, which range from individual practitioners and hospitals to nursing homes, pharmacies, drugstores, and the retail food industry. The company also offers targeted training and employs specialized consultants to support its clientele, further establishing its reputation for medical competence both domestically and internationally.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (09.11.2025):
IVF HARTMANN Holding AG’s latest financial results for the 2024 fiscal year (reported in the March 2025 update) demonstrate strong performance driven by its ongoing Transformation Program. The company recorded sales revenues of EUR 2,407.9 million with an organic sales increase of 2.6% compared to 2023, and achieved a record adjusted EBITDA of EUR 261.4 million, marking the highest earnings in recent years. Key product innovations and structural cost measures have contributed to the notable improvement in profitability, with solid performances observed across all business segments.
Transformation Program Impact
IVF HARTMANN Holding AG’s strategic Transformation Program led to significant earnings improvements of over EUR 50 million, primarily by launching innovative products and implementing effective cost measures, despite challenging market conditions.
Sales and Segment Growth
The company reported robust overall sales revenues, with notable organic growth in key segments: Wound Care reached EUR 608.9 million (4.4% growth), Incontinence Management EUR 769.9 million (1.6% growth), Infection Management EUR 518.9 million (0.6% growth), and Complementary Group Divisions EUR 510.2 million (4.0% growth).
Record Adjusted EBITDA
Adjusted EBITDA increased nearly EUR 60 million, or 29%, to EUR 261.4 million – a record achievement in the company’s history (excluding 2020’s pandemic-related effects). This performance boosted the adjusted EBITDA margin by over 2 percentage points to 10.9%.
Outlook for 2025
Looking ahead, IVF HARTMANN Holding AG anticipates moderate organic sales growth in 2025, with an adjusted EBITDA forecast ranging between EUR 260 and 300 million, underscoring its continued focus on sustaining long-term competitiveness and profitability.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
407 M
Market cap (USD)
175
Daily traded volume (Shares)
151 / 151
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
